Chemistry:Methionitazene
Methionitazene (methylthionitazene) is a benzimidazole derivative which is an opioid designer drug. It was invented in the late 1950s as part of the original research into the "nitazene" group of opioids by CIBA in Switzerland, but as with all compounds from this group was never developed for legitimate medical uses. In early studies on mice, it was found to be around half the potency of the methoxy analogue metonitazene with around 50 times the analgesic potency of morphine, and significantly more potent than the ethylthio homologue,[1] but more recent research using modern techniques found methionitazene and metonitazene to have a similar EC50 in vitro despite the methoxy compound having a stronger binding affinity at the mu opioid receptor.[2]
See also
References
- ↑ "Benzimidazole-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-benzyl-nitro-benzimidazolen.". Helvetica Chimica Acta 43 (4): 1032–1046. 1960. doi:10.1002/hlca.19600430412.
- ↑ "Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro µ-opioid receptor assays and in vivo behavioral studies in mice". Pharmacological Research 210: 107503. December 2024. doi:10.1016/j.phrs.2024.107503. PMID 39521025.
 | 0.00  (0 votes) |
